In:
Transfusion
Authors:
Maite Aubry, Vaea Richard, Jennifer Green, Julien Broult, and Didier Musso
BACKGROUND: Zika virus (ZIKV) is an arthropod-borne virus (arbovirus) transmitted by mosquitoes. The potential for ZIKV transmission through blood transfusion was demonstrated during the ZIKV outbreak that occurred in French Polynesia from October 2013 to April 2014. Pathogen inactivation of blood products is a proactive strategy that provides the potential to reduce transfusiontransmitted diseases. Inactivation of arboviruses by amotosalen and ultraviolet A (UVA) illumination was previously demonstrated for chikungunya, West Nile, and dengue viruses.We report here the efficiency of this process for ZIKV inactivation of human plasma.
STUDY DESIGN AND METHODS: Plasma units were spiked with ZIKV. Viral titers and RNA loads were measured in plasma before and after amotosalen and UVA photochemical treatment.
RESULTS: The mean ZIKV titers and RNA loads in plasma before inactivation were respectively 6.57 log TCID50/mL and 10.25 log copies/mL. After inactivation, the mean ZIKV RNA loads was 9.51 log copies/mL, but cell cultures inoculated with inactivated plasma did not result in infected cells and did not produce any replicative virus after one passage, nor detectable viral RNA from the second passage.
CONCLUSION: In this study we demonstrate that amotosalen combined with UVA light inactivates ZIKV in fresh-frozen plasma. This inactivation process is of particular interest to prevent plasma transfusiontransmitted ZIKV infections in areas such as French Polynesia, where several arboviruses are cocirculating.
Download full publication: